Thrombus Distribution in Vaccine-induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.

Radiology

From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.).

Published: December 2022

Vaccination strategies have been at the forefront of controlling the COVID-19 pandemic. An association between vaccine-induced immune thrombotic thrombocytopenia (VITT) and one of these vaccines, the ChAdOx1 nCov-19 vaccine, is now recognized. The purpose of this study was to investigate the frequency and location of thrombosis in each vascular system using CT, MRI, and US to identify additional sites of thrombus in a United Kingdom-wide sample of patients with confirmed VITT. Thirty-two radiology centers identified through the national collaborative Radiology Academic Network for Trainees were invited from the United Kingdom; seven of these contributed to this study. All patients with confirmed VITT ¬between February 3 and May 12, 2021, who met the inclusion criteria were included. The location and extent of thrombi were evaluated using CT, MRI, and US. A total of 40 patients (median age, 41 years [IQR, 32-52]; 22 [55%] men) with confirmed vaccine-induced immune thrombotic thrombocytopenia after administration of their first ChAdOx1 nCov-19 vaccine were included. Thirty-two patients (80%) developed symptoms within the first 14 days, and eight (20%) developed symptoms within 14-28 days. Twenty-nine patients (72%) experienced neurologic symptoms and were confirmed to have cerebral venous sinus thrombosis, 12 (30%) had clinical deterioration and repeat imaging demonstrated extension of their primary thrombus, and eight (20%) died. Twenty-five of 30 patients (83%) who underwent additional imaging had occult thrombosis. In conclusion, patients with VITT are likely to have multiple sites of thrombosis, with the most frequent being cerebral venous sinus thrombosis in combination with pulmonary embolism and portomesenteric venous thrombosis. Whole-body imaging with contrast-enhanced CT can be used to identify occult thrombosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219093PMC
http://dx.doi.org/10.1148/radiol.220365DOI Listing

Publication Analysis

Top Keywords

vaccine-induced immune
12
immune thrombotic
12
thrombotic thrombocytopenia
12
chadox1 ncov-19
12
ncov-19 vaccine
8
patients confirmed
8
confirmed vitt
8
developed symptoms
8
cerebral venous
8
venous sinus
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!